Coverage / BMY / Trade Card

BMY

Bristol-Myers Squibb Co

BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 62.32 Healthcare - Drug Manufacturers - GeneralAWAIT ENTRY
ACTIONABLEMethodology gates passed
68

Position levels

Currenttoday
USD 62.32
Buy <=wait / entry
USD 52.33
Trim >=take some off
USD 65.00
Thesis breakA material adverse change to Eliquis commercial economics, such as an earlier-th...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case37%100 / 10037.0
Base case47%62 / 10029.1
Bear case16%10 / 1001.6
Weighted conviction68 / 100 - BUY

Top risks

  • FDA approval of combination blood cancer treatment for relapsed/refractory patients
  • Q1 2026 results with reaffirmed 2026 revenue guidance of $46.0 - $47.5B
  • Q2 FY26 earnings beat: revenue $12.97B, earnings $3.32B, profit margin 25.57%
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n